Ji-Hyun Kwon

Dr. Ji-Hyun Kwon


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2016 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
YJYusook Jeong
Yusook Jeong
HHHye Sook Han
Hye Sook Han
HLHyo Duk Lee
Hyo Duk Lee
JYJiyoul Yang
Jiyoul Yang
JJJiwon Jeong
Jiwon Jeong
SKSeung Taik Kim
Seung Taik Kim
Dexamethasone is a mainstay antiemetic regimen for the prevention of chemotherapy-induced nausea and vomiting. The aim of this pilot study was to assess the incidence of and factors associated with steroid-induced diabetes in cancer patients receiving chemotherapy with dexamethasone as an antiemetic. Non-diabetic patients with newly diagnosed gastrointestinal cancer who received at least three cycles of highly or moderately emetogenic chemotherapy with dexamethasone as an antiemetic were enrolled. Fasting plasma glucose levels, 2-hour postprandial glucose levels, and hemoglobin A1C tests for the diagnosis of diabetes were performed before chemotherapy and at 3 and 6 months after the start of chemotherapy. The homeostasis model assessment of insulin resistance (HOMA-IR) was used as an index for measurement of insulin resistance, defined as a HOMA-IR ≥ 2.5. Between January 2012 and November 2013, 101 patients with no history of diabetes underwent laboratory tests for assessment of eligibility; 77 of these patients were included in the analysis. Forty-five patients (58.4%) were insulin resistant and 17 (22.1%) developed steroid-induced diabetes at 3 or 6 months after the first chemotherapy, which included dexamethasone as an antiemetic. Multivariate analysis showed significant association of the incidence of steroid-induced diabetes with the cumulative dose of dexamethasone (p=0.049). We suggest that development of steroid-induced diabetes after antiemetic dexamethasone therapy occurs in approximately 20% of non-diabetic cancer patients; this is particularly significant for patients receiving high doses of dexamethasone.

1 March 2018 in Thrombosis Research
Verified
Journal Article
Closed access
JKJi-Hyun Kwon
Ji-Hyun Kwon
YKYoungil Koh
Youngil Koh
SYSu Jong Yu
Su Jong Yu
JYJung-Hwan Yoon
Jung-Hwan Yoon

15 October 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JKJi-Hyun Kwon
Ji-Hyun Kwon
YKYu Jung Kim
Yu Jung Kim
KLKeun-Wook Lee
Keun-Wook Lee
DODo-Youn Oh
Do-Youn Oh
SPSo-Yeon Park
So-Yeon Park
SHSung Whan Ha
Sung Whan Ha
Background: Whether a systemic adjuvant treatment is needed is an area of controversy in patients with node-negative early breast cancer with tumor size of ≤1 cm, including T1mic. Methods: We performed a retrospective analysis of clinical and pathology data of all consecutive patients with node-negative T1mic, T1a, and T1b invasive ductal carcinoma who received surgery between Jan 2000 and Dec 2006. The recurrence free survival (RFS) and risk factors for recurrence were identified. Results: Out of 3889 patients diagnosed with breast cancer, 375 patients were enrolled (T1mic:120, T1a:93, T1b:162). Median age at diagnosis was 49. After a median follow up of 60.8 months, 12 patients developed recurrences (T1mic:4 (3.3%), T1a:2 (2.2%), T1b:6 (3.7%)), with a five-year cumulative RFS rate of 97.2%. Distant recurrence was identified in three patients. Age younger than 35 years (HR 4.91; 95% CI 1.014-23.763, p = 0.048) and triple negative disease (HR 4.93; 95% CI 1.312-18.519, p = 0.018) were significantly associated with a higher rate of recurrence. HER2 overexpression, Ki-67, and p53 status did not affect RFS. Conclusions: Prognosis of node-negative breast cancer with T1mic, T1a and T1b is excellent, but patients under 35 years of age or with triple negative disease have a relatively high risk of recurrence.

1 January 2019 in Journal of Gastric Cancer
Verified
Journal Article
Open access
JYJieun Yun
Jieun Yun
SHSang-Bae Han
Sang-Bae Han
HKHong Jun Kim
Hong Jun Kim
SGSe-Il Go
Se-Il Go
WLWon Sup Lee
Won Sup Lee
HHHye Sook Han
Hye Sook Han
Yun J, et al. J Gastric Cancer. 2019 Apr;19:e27. https://doi.org/10.5230/jgc.2019.19.e27

30 April 2021 in Blood Research
Verified
Journal Article
Open access
PDF file
JKJi-Hyun Kwon
Ji-Hyun Kwon
Jihyun Kwon. Blood Res 2021;56:S5-S16. https://doi.org/10.5045/br.2021.2020321

1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
SSSeung-Myoung Son
Seung-Myoung Son
CWChang Gok Woo
Chang Gok Woo
OLOk-Jun Lee
Ok-Jun Lee
SLSun Kyung Lee
Sun Kyung Lee
MCMinkwan Cho
Minkwan Cho
HHHye Sook Han
Hye Sook Han
Son SM, et al. J Gastric Cancer. 2024 Dec;25:e2. https://doi.org/10.5230/jgc.2025.25.e2